Cormorant Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Cormorant Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-25,307	Closed	-$178K	–	78
2016 Q3	$178K	Hold	25,307	–	–	0.02%	80
2016 Q2	$206K	Buy	25,307 +307	+1%	+$2.89K	0.03%	80
2016 Q1	$203K	Hold	25,000	–	–	0.03%	82
2015 Q4	$302K	Hold	25,000	–	–	0.04%	80
2015 Q3	$299K	Hold	25,000	–	–	0.05%	84
2015 Q2	$458K	Buy	+25,000	New	+$429K	0.06%	76

Other funds holding ADAP

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Cormorant Asset Management's ADAP Position: Q4 2016 in Review

Cormorant Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2016, closing a stake of 25,307 shares — an estimated $178K sold.

Cormorant Asset Management first reported a position in ADAP in Q2 2015 and held it in 6 quarters. The position peaked at $458K in Q2 2015. 40 funds tracked by Wall St. Rank hold ADAP as of Q4 2016.

Cormorant Asset Management reported no remaining Adaptimmune Therapeutics position as of Q4 2016 after selling out during the quarter.
Cormorant Asset Management sold 25,307 Adaptimmune Therapeutics shares in Q4 2016, an estimated $178K.
Cormorant Asset Management first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 6 quarters.
Cormorant Asset Management's Adaptimmune Therapeutics position peaked at $458K in Q2 2015.
40 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.